S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:FENC

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

$9.88
+0.19 (+1.96%)
(As of 12/8/2022 05:12 PM ET)
Add
Compare
Today's Range
$9.58
▼
$9.92
50-Day Range
$7.63
▼
$9.86
52-Week Range
$3.96
▼
$10.06
Volume
77,669 shs
Average Volume
74,148 shs
Market Capitalization
$259.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.83

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.6% Upside
$14.83 Price Target
Short Interest
Healthy
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.48) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

797th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

131st out of 171 stocks

See Top Rated MarketRank™ Stocks Here
FENC stock logo

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

November 24, 2022 | markets.businessinsider.com
Expert Ratings for Fennec Pharmaceuticals
November 22, 2022 | markets.businessinsider.com
Where Fennec Pharmaceuticals Stands With Analysts
November 22, 2022 | markets.businessinsider.com
4 Analysts Have This to Say About Fennec Pharmaceuticals
November 22, 2022 | markets.businessinsider.com
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
September 26, 2022 | finance.yahoo.com
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor
September 21, 2022 | finance.yahoo.com
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
September 21, 2022 | nasdaq.com
Fennec's Pedmark To Reduce Risk Of Ototoxicity Associated With Cisplatin Scores FDA Nod
September 21, 2022 | finance.yahoo.com
U.S. FDA approves Fennec's hearing loss therapy
September 21, 2022 | finance.yahoo.com
Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)
September 19, 2022 | markets.businessinsider.com
Will Fennec's Pedmark Cross FDA Finish Line This Time?
August 23, 2022 | benzinga.com
Fennec Pharmaceuticals (NASDAQ:FENC), Analyst Ratings, Price Targets, Predictions
August 1, 2022 | finance.yahoo.com
RTP drugmaker secures up to $45M despite regulatory speed bumps
May 12, 2022 | finance.yahoo.com
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
May 6, 2022 | finance.yahoo.com
Inflation crushes market caps of Triangle's biggest public companies – except these ones
May 3, 2022 | finance.yahoo.com
Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?
April 27, 2022 | seekingalpha.com
Fennec refiling gets FDA review for Pedmark to prevent chemotherapy-induced hearing loss in children
April 27, 2022 | finance.yahoo.com
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
April 5, 2022 | baystreet.ca
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TLS, FENC and ASTR
March 28, 2022 | benzinga.com
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, CRNC and CABA
March 25, 2022 | bizjournals.com
After two rejections and no revenue, Fennec again seeks FDA approval
March 25, 2022 | finance.yahoo.com
Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference
March 24, 2022 | nasdaq.com
Fennec Resubmits Pedmark NDA To FDA
March 24, 2022 | marketwatch.com
Fennec Pharmaceuticals Files Again for FDA OK of Pedmark >FENC
March 24, 2022 | seekingalpha.com
Fennec refiles for FDA approval of Pedmark for preventing ototoxicity due to chemotherapy
March 11, 2022 | benzinga.com
SHAREHOLDER ALERT: EHTH ELMS FENC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings
11/11/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FENC
CUSIP
N/A
CIK
1211583
Web
www.fennecpharma.com
Phone
919-636-4530
Fax
919-890-0490
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.83
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+50.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,350,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-214.78%
Return on Assets
-97.25%

Debt

Debt-to-Equity Ratio
8.81
Current Ratio
10.30
Quick Ratio
10.30

Sales & Book Value

Annual Sales
$170,000.00
Price / Sales
1,524.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
16.20

Miscellaneous

Outstanding Shares
26,238,000
Free Float
23,698,000
Market Cap
$259.23 million
Optionable
Optionable
Beta
0.02

Key Executives

  • Mr. Rostislav Raykov (Age 42)
    Pres, CEO & Director
  • Mr. Robert C. Andrade (Age 43)
    Chief Financial Officer
  • Mr. Mark Gowland
    Controller
  • Mr. Lei Fang
    Pres of Pharstat Inc
  • Ms. Anne McKay (Age 64)
    Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price forecast for 2023?

5 Wall Street research analysts have issued twelve-month price targets for Fennec Pharmaceuticals' shares. Their FENC share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's stock price to reach $14.83 in the next year. This suggests a possible upside of 50.9% from the stock's current price.
View analysts price targets for FENC or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2022?

Fennec Pharmaceuticals' stock was trading at $4.40 on January 1st, 2022. Since then, FENC stock has increased by 123.4% and is now trading at $9.83.
View the best growth stocks for 2022 here.

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our FENC earnings forecast.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its earnings results on Friday, November, 11th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.14.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include 683 Capital Management LLC (1.47%), Tamarack Advisers LP (0.67%), Group One Trading L.P. (0.00%), BlackRock Inc. (0.19%), Hartford Financial Management Inc. (0.15%) and Jane Street Group LLC (0.06%).
View institutional ownership trends.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $9.83.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $257.94 million and generates $170,000.00 in revenue each year. The company earns $-17,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 12/8/2022 by MarketBeat.com Staff